Alector, Inc. (ALEC)

NASDAQ • Healthcare

$1.91

+$0.05 (+3.2%)

Market closed

Last close at September 18, 2026 at 20:00 UTC

Open$1.85

Day Range$1.79 - $1.91

Avg. Volume (3M)1.3M

Market Cap$212M

52 Week Range

$1.09$3.4

Next EarningsIn 46 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$3.3M100%

Gross Profitminus cost of goods$3.3M100%

Fundamentals & Financials

Revenue (TTM)

$13.8M

Net Income (TTM)

-$117.8M

EPS (TTM)

-$1.1

ROA (TTM)

-58.1%

Current Ratio

5.26

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+33.3%Q3 2025-$0.3

+19.0%Q4 2025-$0.34

+12.8%Q1 2026-$0.34

+40.0%Q2 2026-$0.21

+8.1%Q3 2026-$0.21

Nov 5

in 46 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Alector, Inc.

Alector, Inc. is a NASDAQ-listed Biotechnology company focused on immuno-neurology, developing therapies that address immune dysfunction in degenerative brain disorders. In FY2025, it generated $21.0 million in revenue. The company works at the intersection of neuroscience and the innate immune system, aiming to change how neurodegenerative disease is treated.

Name

Alector, Inc.

CEO

Arnon Rosenthal

Website

www.alector.com

Industry

Healthcare

Year Founded

2013

Employees

103

Today's Snapshot

AI-generated

ALEC closed 3.2% higher at 1.91, while its sector was flat.

Trading Volume

Above 10d avg 1.7M

1.8M

vs S&P 500 Today

Strong Outperformance

+3.16%

Updated: September 18, 2026 at 20:33 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

ALEC is trading around 1.91 and carries a strong sell posture backed by multiple bearish internals. The ADX reading is elevated and flagged to the downside, while momentum measures such as CCI and MACD are decisively negative; short-, medium- and long-term moving averages sit above the market, indicating the price is behind its trend envelopes. Volatility is high as shown by double-digit ATR percent, and on-balance volume is deeply negative, consistent with distribution. The pivot lies near current levels, reflecting consolidation within the downtrend. Technical takeaway: Strong Sell—momentum, moving-average alignment, high volatility and weak volume reinforce bearish technicals.

All signals

EMA (5 indicators)$2.00 - $2.14
Sell
RSI (14)41.93
Neutral
Stochastic %K (14, 3, 3)5.62
Buy
MACD Level (12, 26)-0.02
Sell

Peers & Related Assets

FATEFate Therapeutics, Inc.

$2.53+0.4%

NKTXNkarta, Inc.

$2.83+0.7%

VORVor Biopharma Inc.

IRDOpus Genetics, Inc.

PEPGPepGen Inc.

ABOSAcumen Pharmaceuticals, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.